

# PRODUCT INFORMATION



## Esomeprazole Magnesium

Item No. 17326

**CAS Registry No.:** 161973-10-0  
**Formal Name:** (T-4)-bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-κO]-1H-benzimidazolato-κN<sup>3</sup>]-magnesium

**Synonyms:** (-)-Omeprazole Magnesium,  
(S)-Omeprazole Magnesium

**MF:** C<sub>34</sub>H<sub>36</sub>MgN<sub>6</sub>O<sub>6</sub>S<sub>2</sub>

**FW:** 713.1


**Purity:** ≥95%

**UV/Vis.:** λ<sub>max</sub>: 302 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Esomeprazole magnesium is supplied as a crystalline solid. A stock solution may be made by dissolving the esomeprazole magnesium in the solvent of choice. Esomeprazole magnesium is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of esomeprazole magnesium in these solvents is approximately 1, 20, and 25 mg/ml, respectively.

Esomeprazole magnesium is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, esomeprazole magnesium should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Esomeprazole magnesium has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Esomeprazole magnesium is a form of the gastric H<sup>+</sup>/K<sup>+</sup>-ATPase inhibitor esomeprazole (Item No. 17303) in a 2:1 complex with magnesium.<sup>1</sup> It reduces aceclofenac-induced ulcer area and lesion index in the stomach in a rat model of gastric ulcer induced by a non-steroidal anti-inflammatory drug (NSAID) when administered at a dose of 20 mg/kg.<sup>2</sup> Formulations containing esomeprazole magnesium have been used as proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease (GERD), *H. pylori* eradication, and hypersecretory conditions, as well as in the prevention of NSAID-associated gastric ulcers.

### References

1. Olbe, L., Carlsson, E., and Lindberg, P. A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. *Nat. Rev. Drug Discov.* **2**(2), 132-139 (2003).
2. Kim, T.H., Thapa, S.K., Lee, D.Y., et al. Pharmacokinetics and anti-gastric ulceration activity of oral administration of aceclofenac and esomeprazole in rats. *Pharmaceutics* **10**(3), 152 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM